Table 3.
Crude and adjusted hazard ratios of switch to third-line (n = 719)
| Characteristics at second-line initiation | N, row % | Crude HR 95% CI | P value | aHR 95% CI | P value |
|---|---|---|---|---|---|
| Gender | |||||
| Female | 24/480 (5.0%) | 1.0 | 1.0 | ||
| Male | 12/239 (5.0%) | 1.01 (0.50–2.01) | 0.99 | 1.09 (0.52–2.29) | 0.81 |
| Age, years | |||||
| 18–30 | 8/156 (5.1%) | 1.0 | 1.0 | ||
| 30–45 | 20/407 (4.9%) | 0.95 (0.42–2.15) | 0.90 | 0.91 (0.39–2.11) | 0.82 |
| ≥ 45 | 8/156 (5.1%) | 0.95 (0.36–2.54) | 0.93 | 0.89 (0.32–2.49) | 0.82 |
| Time on second-line (calculated from start of second-line until 01 August 2012), weeks | |||||
| < 96 | 9/317 (2.8%) | 1.0 | 1.0 | ||
| ≥ 96 | 27/402 (6.7%) | 2.37 (1.11–5.03) | 0.03* | 2.53 (1.03–6.22) | 0.04* |
| Regimen change prior to 01 August 2012 | |||||
| No | 20/493 (4.1%) | 1.0 | |||
| Yes | 16/226 (7.1%) | 1.76 (0.91–3.39) | 0.09 | ||
| Current CD4 count, cells/mm3 | |||||
| < 100 | 4/49 (8.2%) | 2.81 (0.90–8.83) | 0.08 | ||
| 100–200 | 3/61 (4.9%) | 1.66 (0.46–5.96) | 0.43 | ||
| 200–350 | 8/131 (6.1%) | 2.10 (0.85–5.23) | 0.11 | ||
| ≥ 350 | 11/359 (3.1%) | 1.0 | |||
| Never suppressed on second-line ART prior to August 2012 | |||||
| No | 24/505 (4.8%) | 1.0 | 1.0 | ||
| Yes | 9/90 (10.0%) | 2.32 (1.08–4.99) | 0.03* | 3.37 (1.47–7.73) | 0.00* |
| Viral load blips on second-line ART prior to August 2012 | |||||
| 0 | 16/317 (5.1%) | 1.0 | |||
| ≥ 1 | 14/171 (8.2%) | 1.64 (0.80–3.36) | 0.18 | ||
| History of TB | |||||
| No | 30/658 (4.6%) | 1.0 | 1.0 | ||
| Yes | 6/61 (9.8%) | 2.29 (0.95–5.50) | 0.06 | 1.99 (0.81–4.85) | 0.13 |
| Currently on TB treatment | |||||
| No | 34/694 (4.9%) | 1.0 | |||
| Yes | 2/25 (8.0%) | 1.75 (0.42–7.27) | 0.44 | ||
ABC abacavir, 3TC lamivudine, FTC emtricitabine, LPVr lopinavir/ritonavir, TDF tenofovir, AZT zidovudine, ddI didanosine, d4T stavudine, HR hazard ratio, aHR adjusted hazard ratio; * p < 0.05